Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walmart

CVS Health Corp. and Walmart Inc. will stop filling prescriptions for controlled substances ordered by clinicians working for Cerebral Inc. and Done Health, the broadest curbs yet by major pharmacies against the telehealth companies following scrutiny of their prescription practices.

The Wall Street Journal: CVS and Walmart to stop filling controlled-substance prescriptions for telehealth companies Cerebral, Done

(Reuters) -Walmart Inc and CVS Health Corp said on Wednesday they would stop filling prescriptions for controlled substances issued by telehealth startups Cerebral Inc and Done Health.

Walmart, CVS to halt filling prescriptions for controlled substances by Cerebral, Done

General Dynamics

Medtronic

American stocks are not doing well. On Friday, the S&P 500 moved close to a bear market and analysts believe that this will happen in the near term.

Best 3 defensive stocks to buy as the S&P nears a bear market

Kindness for Kidneys International Received an Honorable Mention NEW YORK and WOONSOCKET, R.I. , May 20, 2022 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and CVS Kidney Care®, a CVS Health® (NYSE: CVS) company, are excited to announce that OmniLife was selected as the winner, and Kindness for Kidneys International received an honorable mention, at the 2022 Lyfebulb–CVS Kidney Care® Innovation Challenge: Accelerating Innovations in Kidney Disease to Improve Health Equity and Outcomes.

OmniLife Named Winner of the 2022 Lyfebulb-CVS Kidney Care® Innovation Challenge

Funding will support social care needs and health care providers across The Hawkeye State DES MOINES, Iowa , May 19, 2022 /PRNewswire/ -- Aetna Health of Iowa Inc., dba Aetna Better Health of Iowa, a CVS Health company (NYSE: CVS), announced that it provided investments totaling $225,000 to six community health partners throughout the state. The investments will support local organizations and health care providers who are committed to helping underserved Iowans meet social care needs, including those related to child care, food insecurity and access to preventive care in rural areas.

Aetna Donates $225,000 to Iowa Community Health Partners

AbbVie

Iron Mountain

Coca-Cola

Mondelez

T-Mobile US

UnitedHealth Group

Bear markets are an inevitable if particularly unpleasant part of the market cycle. But investors who hold the best stocks to buy for bear markets can mitigate at least some of the damage.

The 10 Best Stocks for a Bear Market

Costco

Target

With respect to the Retail sector's 2022 Q1 earnings season scorecard, we now have results from 21 of the 34 retailers in the S&P 500 index. Here's how the companies are performing so far and what to expect.

Previewing Retail Sector Earnings as Inflation Climbs

Reputation and customer service can make or break a business. These things also can be linked to rapid growth.

CVS Is the Retailer Americans Are Most Likely to Regret Buying From

Cummins

Intel

Tyson Foods

These six dividend-paying stocks have low P/E multiples, good dividend yields, and low payout ratios, leaving room for share buybacks. The post Six Dividend-Paying Stocks With Low Payout Ratios to Buy appeared first on InvestorPlace.

Six Dividend-Paying Stocks With Low Payout Ratios to Buy

Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.

Here's Why You Should Hold on to CVS Health (CVS) For Now

Pharmacy chain CVS Health Corp said on Tuesday it has limited in-store and online purchases of baby formula products to three per order, citing a supply shortfall and surging consumer demand.

Baby formula shortage forces CVS Health to limit purchases

Walgreens

CVS Health Corp, Walgreens Boots Alliance Inc and Walmart Inc on Tuesday begin a first-of-its-kind trial to determine what the pharmacy chains owe for their role in the opioid epidemic in two Ohio counties, which are seeking $878 million.

Walgreens, CVS, Walmart begin $878 million opioid trial in Ohio

CVS reassures its investors by aggressively purchasing their own shares, deleveraging their balance sheet, and maintaining a growing dividend. The company unlocks new opportunities with their diversification towards home based care.

CVS Health: Share Repurchases, Deleveraged Balance Sheet, And A Dividend Catalyst

Bristol-Myers

GlaxoSmithKline

Moderna

Pfizer

Should investors' be looking at these health care stocks this earnings season?

5 Health Care Stocks For Your May 2022 Watchlist

Looking at stock returns, CVS's 18% growth is much better than Medtronic's -20% change over the last twelve months.

Is There A Better Pick Over Medtronic Stock?

WOONSOCKET, R.I. , May 5, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced that Executive Vice President and Chief Financial Officer Shawn Guertin will participate in a fireside chat with investors at the Bank of America Healthcare Conference on May 12, 2022 at approximately 8:40 am pacific time.

CVS Health to present at the 2022 Bank of America Healthcare Conference

MinuteClinic rolling out new and expanded services focused on women Company continues its long-time support of American Heart Association's® Go Red for Women® movement with in-store fundraising during month of May WOONSOCKET, R.I. , May 5, 2022 /PRNewswire/ -- To highlight the importance of women being proactive about their health, CVS Health (NYSE: CVS) today announced it is once again offering no-cost heart health screenings during National Women's Health Week, May 8 through May 14, at MinuteClinic locations to help women understand their risk for cardiovascular disease – the number one killer of women.

CVS Health Offering No-Cost Heart Health Screenings at MinuteClinic During National Women's Health Week

McDonald's

Philip Morris

AT&T

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

6 undervalued consumer brand stocks worth buying now. The six undervalued stocks have strong consumer brands that will carry them through the end of a recession as they keep paying dividends.

6 Undervalued Consumer Brand Stocks Worth Buying Now Before a Recession Hits

CVS Health Corp (NYSE: CVS) shares are trading higher by 3.97% at $99.79 after the company reported better-than-expected first-quarter EPS and sales results. The company also raised its FY22 EPS guidance.

Why CVS Health Shares Are Rising

CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.

CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up

CVS Health Corporation (NYSE:CVS ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Tom Cowhey - Senior Vice President, Capital Markets Karen Lynch - President and Chief Executive Officer Shawn Guertin - Executive Vice President and Chief Financial Officer Jon Roberts - Executive Vice President and Chief Operating Officer Alan Lotvin - President, Pharmacy Services Dan Finke - President, Healthcare Benefits Conference Call Participants Lisa Gill - JPMorgan Ricky Goldwasser - Morgan Stanley Michael Cherny - Bank of America Steven Valiquette - Barclays Nathan Rich - Goldman Sachs Justin Lake - Wolfe Research A.J. Rice - Credit Suisse Eric Percher - Nephron Research Brian Tanquilut - Jefferies Operator Ladies and gentlemen, good morning and welcome to the CVS Health First Quarter 2022 Earnings Conference Call.

CVS Health Corporation (CVS) CEO Karen Lynch on Q1 2022 Results - Earnings Call Transcript

With its lucrative COVID vaccine and testing franchise on the decline, the nation's largest pharmacy retailer said Wednesday (May 4) that it was looking for ways to deploy new tech to help streamline connectivity with customers while also helping to boost sales and profitability. Although the $125 billion Rhode Island-based healthcare provider now generates about […]

CVS Leans on Tech, Robotics to Drive Post-COVID Efficiencies as Store Count Declines

CVS Health boosted its annual forecast after processing more prescriptions and adding hundreds of thousands of customers to its health insurance business in the first quarter.

CVS boosts outlook as prescription demand outweighs COVID vaccine dip

CVS Health (CVS) delivered earnings and revenue surprises of 3.74% and 1.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CVS Health (CVS) Surpasses Q1 Earnings and Revenue Estimates

CVS Health Corp's (NYSE: CVS) Q1 sales increased 11.2% Y/Y to $76.83 billion, beating the consensus of $75.39 billion. Adjusted operating income increased 6.6% to $4.48 billion primarily due to increased prescription and front store volume, including the sale of COVID-19 OTC test.

News for CVS Health Stock (CVS)